skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B

(2257) Views  (447) Full article downloads

Authors: Lawrence Lai, Chee-Kin Hui, Nancy Leung, George K Lau

Published Date May 2006 Volume 2006:1(3) Pages 255 - 262
DOI: http://dx.doi.org/10.2147/IJN.S

Lawrence Lai1, Chee-Kin Hui2,3,4, Nancy Leung5, George K Lau2,3,4

1Department of Medicine, Caritas Medical Centre, Hong Kong SAR, China; 2Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China; 3Centre for the Study of Liver Disease, The University of Hong Kong, Hong Kong SAR, China; 4Research Centre for Infection and Immunity, The University of Hong Kong, Hong Kong SAR, China; 5Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong SAR, China

Abstract: Chronic hepatitis B virus (HBV) is a serious and life-threatening disease afflicting 350 million of the world’s population. So far, current monotherapy with conventional interferon-alpha, lamivudine, and adefovir dipivoxil remains unsatisfactory. In addition, the use of conventional interferon-alpha needs to be administered subcutaneously daily or thrice weekly and is associated with frequent adverse events. Although nucleoside–nucleotide analogs such as lamivudine and adefovir dipivoxil are well tolerated and can normalize serum alanine aminotransaminase rapidly, 1-year therapy with either lamivudine or adefovir dipivoxil results in low hepatitis B e antigen (HBeAg) seroconversion rates. In HBeAg negative patients, most of the patients would relapse after lamivudine has been discontinued. Pegylated interferon alpha-2a, an immunomodulatory agent, is a new drug that has just completed phase III clinical trials for the treatment of both HBeAg positive and HBeAg negative chronic HBV infection. The advantage of pegylated interferon alpha-2a in achieving sustained virological response over nucleoside–nucleotide analogs is particularly obvious in the HBeAg negative group. In both of these phase III studies, sustained off-treatment response is superior to the use of lamivudine. These recent data put pegylated interferon alpha-2a as the first choice of anti-HBV therapy, especially in young and motivated patients with chronic HBV infection.

Keywords: pegylated interferon alpha-2a, chronic hepatitis B, HBeAg seroconversion, sustained virological response








Readers of this article also read:

Nanofibers and their applications in tissue engineering
Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia
Nano-vectors for efficient liver specific gene transfer
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Amino acid management of Parkinson’s disease: a case study
Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease